SKYE 4.00 ▲ 6.67% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Skye Bioscience Inc.

    NASDAQ: SKYE · Real-Time Price · USD
    4.00
    0.25 (6.67%)
    At close: Sep 05, 2025, 3:59 PM
    4.04
    1.05%
    After-hours: Sep 05, 2025, 07:21 PM EDT
    6.67%
    Bid 3.76
    Market Cap 123.95M
    Revenue (ttm) n/a
    Net Income (ttm) -42.37M
    EPS (ttm) -1.06
    PE Ratio (ttm) -3.77
    Forward PE -2.56
    Analyst Buy
    Ask 4.15
    Volume 557,940
    Avg. Volume (20D) 907,827
    Open 3.85
    Previous Close 3.75
    Day's Range 3.78 - 4.09
    52-Week Range 1.14 - 7.11
    Beta 2.21

    About SKYE

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SKYE
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    2 months ago
    +32.87%
    Skye Bioscience shares are trading higher after th... Unlock content with Pro Subscription
    3 months ago
    +14.97%
    Skye Bioscience shares are trading higher after the company announced a collaboration with Arecor to improve dosing and patient compliance.
    news image

    1 day ago · benzinga.com

    Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

    On Thursday, Skye Bioscience Inc. SKYE reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

    news image

    1 month ago · seekingalpha.com

    Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

    Skye Bioscience, Inc. (NASDAQ:SKYE ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kaitlyn Melanie Arsenault - Chief Financial Officer Puneet S. Arora - Chief Medical...

    news image

    2 months ago · seekingalpha.com

    Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

    Skye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is it...

    news image

    2 months ago · https://www.defenseworld.net

    Squarepoint Ops LLC Buys Shares of 13,546 Skye Bioscience, Inc. (NASDAQ:SKYE)

    Squarepoint Ops LLC bought a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exc...

    news image

    2 months ago · https://www.defenseworld.net

    Squarepoint Ops LLC Takes Position in Skye Bioscience, Inc. (NASDAQ:SKYE)

    Squarepoint Ops LLC acquired a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SE...

    Add to Watchlist